• Explore /
  • Poster
  • / Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART).

Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART).

Abstract Poster

Authors

null

Zakaria Chakrani

Icahn School of Medicine at Mount Sinai, New York, NY

Zakaria Chakrani , George Slade Mellgard , Stephen Mccroskery , Nathaniel Saffran , Nicole Taylor , Bobby Chi-Hung Liaw , William K. Oh , Kai Tsao , Vaibhav G. Patel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 135)

DOI

10.1200/JCO.2023.41.6_suppl.135

Abstract #

135

Poster Bd #

E15

Abstract Disclosures

Similar Posters

First Author: George Slade Mellgard

First Author: Elisa María Fernández Pérez

Poster

2024 ASCO Genitourinary Cancers Symposium

Preliminary reliability of the FACT-RNT in standard-of-care Lu-PSMA therapy of metastatic castration-resistant prostate cancer.

Preliminary reliability of the FACT-RNT in standard-of-care Lu-PSMA therapy of metastatic castration-resistant prostate cancer.

First Author: Lisa Marie Gudenkauf

First Author: George Slade Mellgard